Figure 1From: Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cellsCassini expression in MEFs in response to DMSO, nilotinib, or 8093 resistance to nilotinib. (A) Viability of 8093 ALL cells over the course of a 9-day drug treatment with 16 nM nilotinib. MEFs were physically separated from the ALL cells by a Transwell. At day 9 (arrow), RNA was isolated from MEFs for gene expression profiling. Viability is expressed as total number of viable cells/total cell number. (B) Schematic indicating treatment of MEFs isolated for gene expression profiling. Left, irradiated MEFs were treated with DMSO or 16 nM nilotinib for 9 days. Right, irradiated MEFs were separated from 8093 ALL cells by a Transwell membrane. The co-cultures were treated with DMSO or 16 nM nilotinib for 9 days. (C) Confirmation of cassini expression using real-time RT/PCR on RNA isolated from MEFs. M, MEFs; D, DMSO; n, nilotinib (n = 3). Individual values for biological triplicates of samples M + D, M + n and M + ALL + n are indicated. Values are represented as mean ± SD of duplicate real-time RT/PCR. *p < 0.05 nil + ALL versus DMSO + ALL. (D) Cassini expression in MEFs treated with DMSO or 16 nM nilotinib, alone, or separated from overlying ALL cells by a Transwell membrane on the indicated days of drug treatment with 16 nM nilotinib or with DMSO (n = 1). *p < 0.05 d6 and d10 MEFs exposed to ALL/DMSO compared to MEFs exposed to ALL/nilotinib.Back to article page